Accretion Nutraveda Limited

Accretion Nutraveda Limited

BBSE:ANL
295.00
INR
+5.00
(+1.72%)
1.51BMarket Cap
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
4.01
6.91
22.1
46.41
- -
Basic EPS, GAAP
0.39
1.14
3.45
7
- -
Free Cash Flow per Basic Share
0.93
0.1
-4.27
-21.35
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
0.36
1.5
6.98
49
49
Tangible Book Value per Share
0.36
1.5
6.98
49
49
Basic Weighted Avg Shares
7
7
7
7
7
Sales/Revenue/Turnover
29
50
160
336
- -
Operating Margin (%)
16.42
23.02
21.91
19.81
- -
Depreciation Expense
3
3
2
3
- -
Net Income, GAAP
3
8
25
51
- -
Effective Tax Rate (%)
2.37
10.15
20.69
18.4
- -
Profit Margin (%)
9.67
16.42
15.63
15.08
- -
Working Capital
2
2
57
277
277
LT Debt
14
5
25
38
38
Total Equity
3
11
51
355
355
Return on Invested Capital (%)
- -
36.97
43.41
21.59
- -
Return on Capital (%)
- -
37.16
44.73
22.37
- -
Return on Common Equity (%)
- -
121.94
81.51
25.01
- -

Capital Structure

INR

•

in mil. unless spec.
Sep'26
Mar'26
ST Debt
35
4
LT Borrowings
9
38
LT Finance Leases
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
7
7
Market Capitalization
- -
1,506

Working Capital

INR

•

in mil. unless spec.
Sep'26
Mar'26
Total Current Assets
145
303
Cash, Cash Equivalents & STI
- -
97
Accounts Receivable, Net
80
81
Inventories
51
90
Total Current Liabilities
71
25
Payables & Accruals
- -
- -
ST Debt
35
4
Deferred Revenue
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
602.18%
Free Cash Flow
- -
- -
400.55%
Net Income, GAAP
- -
- -
102.66%
Sales/Revenue/Turnover
- -
- -
110%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
50
2025
- -
- -
160
2026
- -
- -
336

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.14
2025
- -
- -
3.45
2026
- -
- -
7

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Mayur Popatlal Sojitra
Sector
Health technology
Industry
Biotechnology
Address
Ahmedabad India
IPO Date
Feb 4, 2026
Business
Accretion Nutraveda Limited is an India-based Contract Development and Manufacturing Organization (CDMO) that specializes in the research, development, formulation, and commercial manufacturing of Ayurvedic, herbal, and nutraceutical wellness products. The company offers end-to-end contract manufacturing and private labeling services across multiple dosage forms, including tablets, encompassing film-coated, chewable, uncoated, and effervescent formulations; hard gelatin and hydroxypropyl methylcellulose (HPMC) capsules; oral liquids, including herbal syrups, suspensions, and tonics; oral powders, traditional churans, and dietary granules; external topical preparations, such as medicated oils, pain relief balms, ointments, creams, and therapeutic gels; and specialized botanical extracts and nutritional premixes. Its comprehensive portfolio spans multiple therapeutic and health management categories, including liver care and detoxification; bone, joint, and musculoskeletal health; digestive and gastrointestinal support; respiratory care; women’s reproductive and gynecological health; cardiovascular wellness; vitality, vigor, and immune support; pediatric and geriatric nutrition; memory, neurological, and cognitive enhancement; urinary tract care; and dermatological and hair care formulations. The company operates a World Health Organization Good Manufacturing Practice (WHO-GMP) and ISO-certified manufacturing facility situated at Sanand in Ahmedabad, Gujarat. Accretion Nutraveda serves a diversified client base consisting of multinational pharmaceutical corporations, fast-moving consumer goods (FMCG) enterprises, direct-to-consumer (D2C) wellness brands, institutional healthcare distributors, and merchant exporters. Its commercial footprint spans domestic distribution across India as well as international export markets across more than 20 countries, including the United States, Singapore, and Sri Lanka. Founded in March 2021 as Accretion Nutraveda Private Limited and headquartered in Ahmedabad, Gujarat, India, the company underwent a corporate restructuring and converted into a public limited entity under its current name in May 2025. In February 2026, Accretion Nutraveda Limited completed its Initial Public Offering (IPO) and listed its equity shares on the BSE SME platform (Ticker: BSE:ANL), raising approximately INR 24.77 crore in fresh capital. The company allocated the net proceeds to accelerate operational automation, install advanced high-speed manufacturing and packaging machinery at its Sanand facility, expand formulation capacities, and support ongoing working capital requirements to address increasing global demand for certified Ayurvedic and nutraceutical solutions.